Targeting brain tumors with nanoparticles for treatment
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
This study is testing a new kind of tiny particle that can deliver cancer-fighting drugs right to brain tumors, hoping to shrink the tumors and help people with glioblastoma live longer and healthier lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanovalent Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Bozeman, United States) |
| Project ID | NIH-11081824 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of nanoparticle that can cross the blood-brain barrier to deliver cancer-fighting drugs directly to glioblastoma cells. By using these targeted nanoparticles, the goal is to reduce tumor size and improve survival rates for patients with this aggressive brain cancer. The approach involves encapsulating cytotoxic drugs within the nanoparticles, which are designed to bind to tumor cells and release their therapeutic cargo once inside. This innovative method aims to overcome the limitations of traditional chemotherapy for brain tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with glioblastoma or other intractable brain tumors.
Not a fit: Patients with brain tumors that are not glioblastoma or those who are not eligible for nanoparticle therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using nanoparticles for targeted drug delivery in cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Bozeman, United States
- Nanovalent Pharmaceuticals, INC. — Bozeman, United States (Active)
Researchers
- Principal investigator: Nagy, Jon Owen — Nanovalent Pharmaceuticals, INC.
- Study coordinator: Nagy, Jon Owen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.